TrialInternational urology and nephrology2023

Prospective multicentre randomized double-blind placebo-controlled parallel group study on the efficacy and tolerability of StroVac® in patients with recurrent symptomatic uncomplicated bacterial urinary tract infections.

S Nestler et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.